Why Is DR REDDYS LABS LTD ADR (RDY) Stock Moving Today?

Dr. Reddy’s Laboratories Ltd (RDY) fell 9.39% to $11.38 in a session marked by a sharp reaction to mixed Q1 FY2027 results and external headwinds. The stock declined after the company reported earnings and revenue below expectations, with additional pressure from political developments threatening new tariffs on generic drugs. The earnings call highlighted challenges in the U.S. market and delays in launching key products like semaglutide.

What Happened

Dr. Reddy’s Laboratories released Q1 FY2027 results that showed a GAAP EPS of $0.06, missing the $0.17 estimate, and revenue of $853 million, falling short of the $925.53 million forecast. The company also announced a 5.5% year-over-year revenue decline and a profit plunge. During the earnings call, executives noted that launching generic semaglutide tablets in the U.S. is not currently practical due to the tariff environment. The company is working to resume supplies and hopes to bring semaglutide to market by November. These developments, combined with the broader political risk of Trump-era tariff threats, contributed to the sharp sell-off.

What The Data Shows

RDY has a market cap of $10.5 billion and a P/E ratio of 23.1. Despite a 3.2% revenue increase in the trailing twelve months, the stock has underperformed, trading below its 52-week high of $15.67 and near its 52-week low of $12.19. The stock’s beta of 0.26 suggests it is less volatile than the market, but the recent move indicates heightened sensitivity to sector-specific risks. Short-term sentiment has improved slightly, with a 7-day average of 52 out of 100 compared to a 30-day average of 46. However, the sharp drop suggests market skepticism about the company’s near-term outlook.

What To Watch

The company’s next key event is its scheduled earnings release on July 22, 2026. Investors will be watching for further updates on semaglutide progress and how the company navigates the evolving regulatory and tariff landscape.